c-Fms-IN-1

CAS No. 885703-64-0

c-Fms-IN-1( —— )

Catalog No. M32824 CAS No. 885703-64-0

c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 56 Get Quote
10MG 93 Get Quote
25MG 165 Get Quote
50MG 259 Get Quote
100MG 366 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    c-Fms-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).
  • Description
    c-Fms-IN-1 is a FMS kinase inhibitor with an IC50 of 0.0008 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    CSF1R
  • Recptor
    c-Fms
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    885703-64-0
  • Formula Weight
    393.48
  • Molecular Formula
    C22H27N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 5 mg/mL (12.71 mM; Ultrasonic )
  • SMILES
    CN1CCN(CC1)c1ccc(NC(=O)c2ccc(o2)C#N)c(c1)N1CCCCC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Illig CR, et al. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. Bioorg Med Chem Lett. 2008 Mar 1;18(5):1642-8.?
molnova catalog
related products
  • Edicotinib

    Edicotinib (JNJ 40346527, PRV 6527) is a potent, selective, orally bioavailable CSF-1R inhibitor with IC50 of 3.2 nM; shows weak affinity for KIT and FLT3 (IC50= 20 nM and 190 nM, respectively).

  • Vimseltinib

    DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).

  • Mavrilimumab

    Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that targets the α subunit of the granulocytic-macrophage colony-stimulating factor (GM-CSF) receptor, inhibiting downstream intracellular GM-CSF signaling.